Company Filing History:
5 out of 11 
3 out of 30 
1 out of 1,342 
Years Active: 2021-2025
Title: Innovations and Contributions of Angelica N Sanabria
Introduction
Angelica N Sanabria is a prominent inventor based in La Jolla, California. She has made significant contributions to the field of immunotherapy, holding a total of eight patents. Her work focuses on developing targeted therapies for various diseases, including cancer.
Latest Patents
Among her latest patents is the development of CLL-1 targeted immunotherapies. This patent provides improved CLL-1 targeting polypeptides and compositions for adoptive T cell therapies aimed at treating, preventing, or ameliorating symptoms of cancer, infectious diseases, autoimmune diseases, inflammatory diseases, and immunodeficiencies. Another notable patent involves DLL3 single domain antibodies and therapeutic compositions. This patent includes binding polypeptides that specifically bind DLL3, as well as fusion proteins and pharmaceutical compositions for treating diseases such as cancer.
Career Highlights
Angelica has worked with notable companies in the biotechnology sector, including Inhibrx Biosciences, Inc. and Inhibrx, Inc. Her innovative work has positioned her as a key figure in the development of advanced therapeutic solutions.
Collaborations
Throughout her career, Angelica has collaborated with esteemed colleagues, including John C Timmer and Brendan P Eckelman. These partnerships have further enhanced her research and development efforts in the field of immunotherapy.
Conclusion
Angelica N Sanabria's contributions to immunotherapy through her patents and collaborations highlight her role as an influential inventor. Her work continues to pave the way for advancements in treating complex diseases.